QIAGEN N.V. (QGEN) — Analysis Summary
QIAGEN N.V. (QGEN) has a market cap of $9.03B with year-over-year revenue growth of +5.7%. Net margin stands at 20.3%. The stock trades at a P/E ratio of 21.3.
Key Takeaways
- Revenue changed +5.7% year-over-year
- Net margin of 20.3%
- P/E ratio of 21.3
Compared with its sector, QGEN posted revenue growth of +5.7% and trades at a P/E of 21.3.
QIAGEN N.V. (QGEN)
UPDATED — ET · MARKET DATA POLYGON · FINANCIALS SEC EDGAR
Red Flags & WarningsNo Major Flags
No major credit, margin, or trend red flags were triggered from the latest filings.
Qiagen offers proprietary sample and assay technology to extract, purify, amplify, and interpret DNA, RNA, and proteins. The company's sales are split almost evenly between applications in life sciences and molecular diagnostics. Qiagen generates nearly 90% of its revenue from consumables, with the balance coming from instrumentation and related services. The Americas account for the largest portion of the firm's revenue (52% of 2024 sales), followed by Europe, the Middle East, and Africa (33%) and Asia-Pacific (15%).
Employees
5,500
Exchange
XNYS
Systematic competitive advantage assessment based on 4yr data
This assessment is based on quantitative analysis of historical financial data and does not constitute investment advice. Moat ratings may change with industry and competitive dynamics.
First version surfaces recent SEC Forms 3, 4, and 5 activity. It does not yet parse individual buy/sell transactions.
Capital Structure
Cash Flow
Annual Dividend/Share
$0.35
Dividend Yield
0.81%
Dividend History
Disclaimer: This is not financial advice. Data sourced from SEC EDGAR and Polygon.io. Past performance does not guarantee future results. Always conduct your own research before making investment decisions.